Fig. 6: XPO1 reconstitution restores rRNA and Mcl-1 expression and drug resistance upon KPT-330 and A-1331852. | Cell Death & Disease

Fig. 6: XPO1 reconstitution restores rRNA and Mcl-1 expression and drug resistance upon KPT-330 and A-1331852.

From: XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis

Fig. 6

a U251 and H1299 cells expressing different XPO1 variants were treated with 1 μM or 10 μM of KPT-330 for 24 h and subjected to western blot. b Real-time PCR analysis of indicated RNAs in C528S mutant-expressing U251 cells treated with KPT-330 (1 μM) for 24 h. (mean ± SEM, n = 5). *P < 0.05. c U251 and H1299 cells overexpressing different XPO1 variants were treated with indicated dose of KPT-330 (K) and with or without 1 μM of A-1331852 (A) for 48 h. Cell viability was measured by the MTT assay (mean ± SEM, n = 3 for U251 and n = 2 for H1299). IC50s were listed on the right. d U251 and H1299 cells expressing different XPO1 variants were treated with 1 μM or 10 μM of KPT-330 for 24 h and further with A-1331852 (1 μM) for 24 h, then subjected to flow cytometry analysis for the sub-G1 phase. (mean ± SD, n = 3). *P < 0.05. e Western blot of indicated proteins in shMcl-1- and/or C528S mutant-expressing U251 cells treated with KPT-330 (1 μM) for 24 h. f Cells treated as in e were further treated with A-1331852 (1 μM) for 24 h and subjected to flow cytometry for the sub-G1 phase (mean ± SD, n = 3). *P < 0.05. α-Tubulin was used as the loading control

Back to article page